Company News

Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of…

Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued…

Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia. 

Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant…

Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include:…

Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval.

Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.

On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon.

Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.

Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more…